Skip to main content
Top
Published in: Antimicrobial Resistance & Infection Control 1/2020

01-12-2020 | Care | Research

Epidemiology of Carbapenem-resistant Enterobacteriaceae in Egyptian intensive care units using National Healthcare–associated Infections Surveillance Data, 2011–2017

Authors: Sara Kotb, Meghan Lyman, Ghada Ismail, Mohammad Abd El Fattah, Samia A. Girgis, Ahmed Etman, Soad Hafez, Jehan El-Kholy, Maysaa El Sayed Zaki, Hebat-allah G. Rashed, Ghada M. Khalil, Omar Sayyouh, Maha Talaat

Published in: Antimicrobial Resistance & Infection Control | Issue 1/2020

Login to get access

Abstract

Objective

To describe the epidemiology of carbapenem-resistant Enterobacteriaceae (CRE) healthcare-associated infections (HAI) in Egyptian hospitals reporting to the national HAI surveillance system.

Methods

Design: Descriptive analysis of CRE HAIs and retrospective observational cohort study using national HAI surveillance data. Setting: Egyptian hospitals participating in the HAI surveillance system. The patient population included patients admitted to the intensive care unit (ICU) in participating hospitals. Enterobacteriaceae HAI cases were Klebsiella, Escherichia coli, and Enterobacter isolates from blood, urine, wound or respiratory specimen collected on or after day 3 of ICU admission. CRE HAI cases were those resistant to at least one carbapenem. For CRE HAI cases reported during 2011–2017, a hospital-level and patient-level analysis were conducted using only the first CRE isolate by pathogen and specimen type for each patient. For facility, microbiology, and clinical characteristics, frequencies and means were calculated among CRE HAI cases and compared with carbapenem-susceptible Enterobacteriaceae HAI cases through univariate and multivariate logistic regression using STATA 13.

Results

There were 1598 Enterobacteriaceae HAI cases, of which 871 (54.1%) were carbapenem resistant. The multivariate regression analysis demonstrated that carbapenem resistance was associated with specimen type, pathogen, location prior to admission, and length of ICU stay. Between 2011 and 2017, there was an increase in the proportion of Enterobacteriaceae HAI cases due to CRE (p-value = 0.003) and the incidence of CRE HAIs (p-value = 0.09).

Conclusions

This analysis demonstrated a high and increasing burden of CRE in Egyptian hospitals, highlighting the importance of enhancing infection prevention and control (IPC) programs and antimicrobial stewardship activities and guiding the implementation of targeted IPC measures to contain CRE in Egyptian ICU’s .
Literature
2.
go back to reference Logan LK, Weinstein RA. The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace. J Infect Dis. 2017;215(suppl_1):S28–36.CrossRef Logan LK, Weinstein RA. The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace. J Infect Dis. 2017;215(suppl_1):S28–36.CrossRef
6.
go back to reference Elbadawi LI, Borlaug G, Gundlach KM, et al. Carbapenem-resistant Enterobacteriaceae transmission in health care facilities — Wisconsin, February–may 2015. MMWR Morb Mortal Wkly Rep. 2016;65:906–9.CrossRef Elbadawi LI, Borlaug G, Gundlach KM, et al. Carbapenem-resistant Enterobacteriaceae transmission in health care facilities — Wisconsin, February–may 2015. MMWR Morb Mortal Wkly Rep. 2016;65:906–9.CrossRef
8.
go back to reference (MMWR CDC) Vital Signs: Carbapenem-Resistant Enterobacteriaceae, Morbidity and Mortality Weekly Report (MMWR), March 8, 2013 / 62(09);165–170, On March 5, this report was posted as an MMWR Early Release on the MMWR website (http://www.cdc.gov/mmwr). (MMWR CDC) Vital Signs: Carbapenem-Resistant Enterobacteriaceae, Morbidity and Mortality Weekly Report (MMWR), March 8, 2013 / 62(09);165–170, On March 5, this report was posted as an MMWR Early Release on the MMWR website (http://​www.​cdc.​gov/​mmwr).
9.
go back to reference Ling ML, Tee YM, Tan SG, et al. Risk factors for acquisition of carbapenem resistant Enterobacteriaceae in an acute tertiary care hospital in Singapore. Antimicrob Resist Infect Control. 2015;4:26.CrossRef Ling ML, Tee YM, Tan SG, et al. Risk factors for acquisition of carbapenem resistant Enterobacteriaceae in an acute tertiary care hospital in Singapore. Antimicrob Resist Infect Control. 2015;4:26.CrossRef
11.
go back to reference Kofteridis DP, Valachis A, Dimopoulou D, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonization: a case-case–control study. J Infect Chemother. 2014;20:293–7.CrossRef Kofteridis DP, Valachis A, Dimopoulou D, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonization: a case-case–control study. J Infect Chemother. 2014;20:293–7.CrossRef
12.
go back to reference Vardakas KZ, Matthaioud DK, Falagas ME, Antypa E, Kotelie A. Eleni Antoniadou: Characteristics, risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in the intensive care unit. J Infect. June 2015;70(6):592–9.CrossRef Vardakas KZ, Matthaioud DK, Falagas ME, Antypa E, Kotelie A. Eleni Antoniadou: Characteristics, risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in the intensive care unit. J Infect. June 2015;70(6):592–9.CrossRef
14.
go back to reference See I, Lessa F. Incidence and pathogen distribution of healthcare-associated infections in pilot hospitals in Egypt. Infect Control Hosp Epidemiol. 2013;34:1281–8.CrossRef See I, Lessa F. Incidence and pathogen distribution of healthcare-associated infections in pilot hospitals in Egypt. Infect Control Hosp Epidemiol. 2013;34:1281–8.CrossRef
15.
go back to reference Talaat M, et al. National surveillance of health care–associated infections in Egypt: developing a sustainable program in a resource-limited country. Am J Infect Control. 2016;44:1296–301.CrossRef Talaat M, et al. National surveillance of health care–associated infections in Egypt: developing a sustainable program in a resource-limited country. Am J Infect Control. 2016;44:1296–301.CrossRef
18.
go back to reference Weiner LM, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect Control Hosp Epidemiol. 2016;37(11):1288–301.CrossRef Weiner LM, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect Control Hosp Epidemiol. 2016;37(11):1288–301.CrossRef
19.
go back to reference CLSI. Performance standards for antimicrobial susceptibility testing: twenty-fifth CLSI supplement M100-S25. Wayne (PA): Clinical and Laboratory Standards Institute; 2015. CLSI. Performance standards for antimicrobial susceptibility testing: twenty-fifth CLSI supplement M100-S25. Wayne (PA): Clinical and Laboratory Standards Institute; 2015.
22.
go back to reference StataCorp. Stata statistical software: release 13. College Station, TX: StataCorp LP; 2013. StataCorp. Stata statistical software: release 13. College Station, TX: StataCorp LP; 2013.
24.
go back to reference Xu Y, Gu B, Hunag M, Liu H, Xu T, Xia W, et al. Epidemiology of Carbapenem resistant Enterobacteriaceae (CRE). J Thorac Dis. 2015;7:376–85.PubMedPubMedCentral Xu Y, Gu B, Hunag M, Liu H, Xu T, Xia W, et al. Epidemiology of Carbapenem resistant Enterobacteriaceae (CRE). J Thorac Dis. 2015;7:376–85.PubMedPubMedCentral
25.
go back to reference Mitgang EA, Hartley DM, Malchione MD, Koch M, Goodman JL. Review and mapping of carbapenem-resistant Enterobacteriaceae in Africa: using diverse data to inform surveillance gaps. Int J Antimicrob Agents. 2018;52(3):372–84 ISSN 0924-8579.CrossRef Mitgang EA, Hartley DM, Malchione MD, Koch M, Goodman JL. Review and mapping of carbapenem-resistant Enterobacteriaceae in Africa: using diverse data to inform surveillance gaps. Int J Antimicrob Agents. 2018;52(3):372–84 ISSN 0924-8579.CrossRef
26.
go back to reference Ssekatawa K, Byarugaba DK, Wampande E, Ejobi F. A systematic review: the current status of carbapenem resistance in East Africa. BMC Res Notes. 2018;11(1):629.CrossRef Ssekatawa K, Byarugaba DK, Wampande E, Ejobi F. A systematic review: the current status of carbapenem resistance in East Africa. BMC Res Notes. 2018;11(1):629.CrossRef
27.
go back to reference Thaden JT, Lewis SS, Hazen KC, et al. Rising rates of Carbapenem-resistant Enterobacteriaceae in community hospitals: A mixed-methods review of epidemiology and microbiology practices in a network of community hospitals in the southeastern United States. Infect Control Hosp Epidemiol. 2014;35(8):978–83.CrossRef Thaden JT, Lewis SS, Hazen KC, et al. Rising rates of Carbapenem-resistant Enterobacteriaceae in community hospitals: A mixed-methods review of epidemiology and microbiology practices in a network of community hospitals in the southeastern United States. Infect Control Hosp Epidemiol. 2014;35(8):978–83.CrossRef
28.
go back to reference Brennan BM, Coyle JR, Marchaim D, et al. Statewide surveillance of Carbapenem-resistant Enterobacteriaceae in Michigan. Infect Control Hosp Epidemiol. 2014;35:342–9.CrossRef Brennan BM, Coyle JR, Marchaim D, et al. Statewide surveillance of Carbapenem-resistant Enterobacteriaceae in Michigan. Infect Control Hosp Epidemiol. 2014;35:342–9.CrossRef
30.
go back to reference Centers for Disease Control and Prevention. Facility Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE). November 2015 Update - CRE Toolkit In: National Center for Emerging and Zoonotic Infectious Diseases, Division of Healthcare Quality Promotion, editors. Atlanta: Centers for Disease Control and Prevention; 2015. Centers for Disease Control and Prevention. Facility Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE). November 2015 Update - CRE Toolkit In: National Center for Emerging and Zoonotic Infectious Diseases, Division of Healthcare Quality Promotion, editors. Atlanta: Centers for Disease Control and Prevention; 2015.
31.
33.
go back to reference Correa L, Martino MDV, Siqueira I, et al. A hospital-based matched case–control study to identify clinical outcome and risk factors associated with carbapenem-resistant Klebsiella pneumoniae infection. BMC Infect Dis. 2013;13:80.CrossRef Correa L, Martino MDV, Siqueira I, et al. A hospital-based matched case–control study to identify clinical outcome and risk factors associated with carbapenem-resistant Klebsiella pneumoniae infection. BMC Infect Dis. 2013;13:80.CrossRef
34.
go back to reference Sopirala M, Ssali F, Liao S, Simbartl L, Kralovic S. Risk Factor and Outcome Evaluation in Patients With Carbapenem-Resistant Enterobacteriaceae in a Mid-Western Tertiary Care Academic Medical Center. Open Forum Infect Dis. 2016;3(suppl_1):334.CrossRef Sopirala M, Ssali F, Liao S, Simbartl L, Kralovic S. Risk Factor and Outcome Evaluation in Patients With Carbapenem-Resistant Enterobacteriaceae in a Mid-Western Tertiary Care Academic Medical Center. Open Forum Infect Dis. 2016;3(suppl_1):334.CrossRef
35.
go back to reference MuralidharVarmaa L, RohitReddya V, SudhaVidyasagara, AvinashHollaa. Nanda KrishnaBhata Risk factors for carbapenem resistant Enterobacteriaceae in a teritiary hospital—A case control study Indian. J Med Spec. 2018;9(4):178–83.CrossRef MuralidharVarmaa L, RohitReddya V, SudhaVidyasagara, AvinashHollaa. Nanda KrishnaBhata Risk factors for carbapenem resistant Enterobacteriaceae in a teritiary hospital—A case control study Indian. J Med Spec. 2018;9(4):178–83.CrossRef
36.
go back to reference Moemen D, Doaa T. Masallat: Prevalence and characterization of carbapenem-resistant Klebsiella pneumoniae isolated from intensive care units of Mansoura University hospitals Egyptian. Aust J Basic Appl Sci. 2017;4:37–41. Moemen D, Doaa T. Masallat: Prevalence and characterization of carbapenem-resistant Klebsiella pneumoniae isolated from intensive care units of Mansoura University hospitals Egyptian. Aust J Basic Appl Sci. 2017;4:37–41.
37.
go back to reference ElMahallawy HA, Zafer MM, Amin MA, Ragab MM, Al-Agamy MH. Spread of carbapenem resistant Enterobacteriaceae at tertiary care cancer hospital in Egypt. Infect Dis. 2018;50(7):560–4.CrossRef ElMahallawy HA, Zafer MM, Amin MA, Ragab MM, Al-Agamy MH. Spread of carbapenem resistant Enterobacteriaceae at tertiary care cancer hospital in Egypt. Infect Dis. 2018;50(7):560–4.CrossRef
38.
go back to reference El-Sweify MA, Gomaa NI, El-Maraghy NN, Mohamed HA. Phenotypic detection of carbapenem resistance among Klebsiella pneumoniae in Suez Canal university hospitals, Ismailiya. Egypt Int J Curr Microbiol App Sci. 2015;4:10–8. El-Sweify MA, Gomaa NI, El-Maraghy NN, Mohamed HA. Phenotypic detection of carbapenem resistance among Klebsiella pneumoniae in Suez Canal university hospitals, Ismailiya. Egypt Int J Curr Microbiol App Sci. 2015;4:10–8.
Metadata
Title
Epidemiology of Carbapenem-resistant Enterobacteriaceae in Egyptian intensive care units using National Healthcare–associated Infections Surveillance Data, 2011–2017
Authors
Sara Kotb
Meghan Lyman
Ghada Ismail
Mohammad Abd El Fattah
Samia A. Girgis
Ahmed Etman
Soad Hafez
Jehan El-Kholy
Maysaa El Sayed Zaki
Hebat-allah G. Rashed
Ghada M. Khalil
Omar Sayyouh
Maha Talaat
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Antimicrobial Resistance & Infection Control / Issue 1/2020
Electronic ISSN: 2047-2994
DOI
https://doi.org/10.1186/s13756-019-0639-7

Other articles of this Issue 1/2020

Antimicrobial Resistance & Infection Control 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.